Journal article
Molecular radionuclide imaging of pancreatic neoplasms
The lancet. Gastroenterology & hepatology, Vol.4(7), pp.559-570
07/01/2019
DOI: 10.1016/S2468-1253(19)30081-0
PMID: 31169124
Abstract
Pancreatic neoplasms have high morbidity and dismal prognosis. Substantial progress in translational research and advances in scanner technology have resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice. Metabolic imaging with F-18-FDG PET has extensive utility in the staging, assessment of treatment response, and follow-up of pancreatic ductal adenocarcinoma. Integrated PET/MRI has the potential to further expand this utility and lead to innovative applications. Somatostatin receptor PET imaging has had a profound effect on the evaluation and management of pancreatic neuroendocrine tumours. Peptide receptor radionuclide therapy is a new frontier in personalised medicine because it customises treatment to the unique biological features of a patient and the molecular signature of the patient's tumour. Further investigation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients with pancreatic neoplasms.
Details
- Title: Subtitle
- Molecular radionuclide imaging of pancreatic neoplasms
- Creators
- Ananya Panda - Mayo Clinic in ArizonaIshan Garg - Mayo Clinic in ArizonaGeoffrey B. Johnson - Mayo Clinic in ArizonaMark J. Truty - Mayo Clinic in ArizonaThorvardur R. Halfdanarson - Mayo Clin, Dept Med Oncol, Rochester, MN USAAjit H. Goenka - Mayo Clinic in Arizona
- Resource Type
- Journal article
- Publication Details
- The lancet. Gastroenterology & hepatology, Vol.4(7), pp.559-570
- Publisher
- Elsevier
- DOI
- 10.1016/S2468-1253(19)30081-0
- PMID
- 31169124
- ISSN
- 2468-1253
- eISSN
- 2468-1253
- Number of pages
- 12
- Language
- English
- Date published
- 07/01/2019
- Academic Unit
- Radiology
- Record Identifier
- 9984697718202771
Metrics
4 Record Views